Insider buying last 90 days
No open-market insider purchases were filed for HRMY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every HRMY insider filing, plotted on the chart in Gekko.Open HRMY in Gekko
NASDAQ: HRMY
Harmony Biosciences (HRMY) Stock Analysis & Forecast
Oct 12 close
$38.23−2.05 (−5.1%)
Gekko Brief
Oct 12 closeHarmony Biosciences closed at $38.23 on 12 October 2026, -5.1% on the day. The price sits between the 50-day ($39.99) and 200-day ($34.67) moving averages, inside a 52-week range of $25.52 to $43.49. The GekkoIndex reads 65.3, in the Accumulation zone, up 4.1 points over five sessions. Gekko Fair Value is $63.51, so the price is 39.8% below it.
The next earnings report is due on 3 November 2026, 22 days away (before open). Over the last 8 reports the company beat the earnings estimate 4 times, with an average move of 5.8% across the report. Seasonally, the next 20 trading days from this point averaged +7.3% over the last 5 years, rising in 4 of them.
9 firms rate the stock: 4 buy, 4 hold and 1 sell, with a consensus target of $47.64. A typical daily move is about 3.9%, and a typical 20-day move about 8.6%. On the swing-trade checklist, 3 items read supportive and 1 reads as a headwind (earnings risk).
A plain summary of the figures as of the Oct 12, 2026 close.
Harmony Biosciences price vs fair value
Close $38.23200-day averageGekko Fair Value $63.51
Harmony Biosciences quick facts
- Market cap
- $2.21B
- P/E ratio
- 12.8
- Forward P/E
- 10.1
- EPS, TTM
- $3.10
- Revenue, TTM
- $959.9M
- Profit margin
- 18.9%
- Dividend yield
- —
- Beta
- 1.01
- Volume
- 1.15M avg 976,186
- 1-year return
- +42.8%
- Typical daily move
- ±3.9%
- Typical 20-day move
- ±8.6%
- 50-day average
- $39.99
- 200-day average
- $34.67
- Next earnings
- Nov 3 before open
- Shares outstanding
- 58.24M
Harmony Biosciences swing-trade checklist
Harmony Biosciences scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $38.23 sits between the 50-day ($39.99) and 200-day ($34.67) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
65.3, Accumulation
Reading 65.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
39.8% below
Price is 39.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.3% on average
From this point in the calendar, the next 20 trading days averaged +7.3% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Harmony Biosciences stock chart and price history
Harmony Biosciences closed at $38.23 on Oct 12, 2026, +42.8% over the past year, inside a 52-week range of $25.52 to $43.49.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −7.9%
- 3 months
- +9.8%
- 6 months
- +31.6%
- 1 year
- +42.8%
The full HRMY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open HRMY in Gekko
Follow Harmony Biosciences through every session
Put HRMY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track HRMY in GekkoFree for 7 days. No credit card required.
About Harmony Biosciences
Harmony Biosciences develops and sells medicines for people in the United States living with rare neurological disorders, and it has already moved past the early research stage into commercial sales. Its best-known product is WAKIX, a prescription treatment aimed at adults with narcolepsy who experience excessive daytime sleepiness.
The company's work centers on bringing this kind of therapy to patients who have few other treatment options, generating revenue through sales of its approved medication rather than through licensing or early-stage research deals alone.
Harmony Biosciences is headquartered in Plymouth Meeting, Pennsylvania, and traces its roots back to 2017, when it was known as Harmony Biosciences II, Inc. before taking its present name in February 2020. Its shares are listed on the NASDAQ under the ticker HRMY.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- harmonybiosciences.com
Harmony Biosciences GekkoIndex: the smart money zone
Harmony Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.3, in the Accumulation zone, up 4.1 points over five sessions.
65.3Accumulation
Up 4.1 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 33 | −1.1% | +1.8% | ||
| Accumulation (current zone) | 217 | +0.9% | +3.4% | ||
| Neutral | 405 | +0.1% | +0.3% | ||
| Distribution | 26 | −0.3% | +0.6% | ||
| Selling | 1 | Too few readings yet | |||
Average HRMY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the HRMY price, zone by zone.Track HRMY in Gekko
Is Harmony Biosciences stock overvalued? Gekko Fair Value
Harmony Biosciences trades 39.8% below Gekko Fair Value of $63.51, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Harmony Biosciences shares are worth, recalculated every trading day.
$63.51
Gekko Fair Value, Oct 10, 2026
39.8% Undervalued
At the end of Aug 2026 the price was 45.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open HRMY in Gekko
Harmony Biosciences insider and Congress trading
No open-market insider purchases were filed for Harmony Biosciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in HRMY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for HRMY, plotted on the chart in Gekko.Open HRMY in Gekko
Buybacks
Harmony Biosciences has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.08M
- As a share of market cap
- 0.05%
From company filings.
Harmony Biosciences earnings: next date and track record
Harmony Biosciences reports on Nov 3, 2026, before the open (22 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected before the open, 22 days away
- EPS estimate
- $1.11
- Revenue estimate
- $274.5M
4 of 8reports beat the EPS estimate
±5.8%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- Harmony Biosciences reported a strong Q2 2026: WAKIX delivered record net revenue of $261.3M (up 30% YoY, 21% QoQ) with estimated average patients of ~8,950 and confirmation of full-year net revenue guidance of $1.00B to $1.04B. Management emphasized the company is profitable, cash-generative, and has ~$962.5M in cash and investments. R&D momentum centered on BP-205, a potential best-in-class orexin-2 receptor agonist, with encouraging Phase I single ascending dose (SAD) PK/safety data (rapid Tmax 30–75 min, mean half-life ~25 hours, dose-proportional exposure, high potency and selectivity). Multiple data catalysts were identified: MAD data due in Q4, a sleep-deprived healthy volunteer study with data early 2027, and planned Phase II initiations mid-next year. Business development priorities target assets with 2028–2032 revenue potential, and the company is pursuing IP protection for pitolisant (franchise protected into March 2030; potential extensions and BP-205 composition patents through 2043). Ongoing ANDA litigation remains (one ANDA filer outstanding), and BP-205 MAD signaled transient target-engagement adverse events (insomnia, polyuria). Overall, the call was confident and growth-oriented with a clear commercial and R&D narrative.
- Guidance
- Full-year net revenue guidance reaffirmed at $1.00 billion to $1.04 billion. Clinical development timing guidance: MAD data for BP-205 expected in Q4 2026; sleep-deprived healthy volunteer data early 2027; multiple Phase II starts mid-2027. Expectation of continued strong cash flow and intent to deploy cash (~$963M) toward strategic BD and pipeline investments.
- Risks flagged
- Ongoing ANDA litigation (one remaining filer; bench trial concluded for one patent with closing arguments scheduled Oct 22); potential class-related and off-target adverse events for BP-205 (insomnia, polyuria observed in MAD, hepatotoxicity/cardiac risk discussed as something BP-205 was designed to avoid); competitive risk in orexin space and from other orexin-2 agonists; payer and seasonal market access headwinds that can delay patient starts; reliance on WAKIX as primary revenue driver; clinical and regulatory risk inherent to development programs.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $1.28 est $0.97 | $261.3M est $250.8M | +7.4% |
| May 7, 2026 | $0.79 est $0.93 | $215.4M est $220.8M | −5.5% |
| Feb 24, 2026 | $0.57 est $0.86 | $243.8M est $240.3M | +4.9% |
| Nov 4, 2025 | $1.08 est $0.86 | $239.5M est $240.0M | +6.9% |
| Aug 5, 2025 | $0.68 est $0.72 | $200.5M est $220.2M | −2.4% |
| May 6, 2025 | $0.78 est $0.91 | $184.7M est $206.1M | +11.6% |
| Feb 25, 2025 | $1.08 est $0.82 | $201.3M est $183.2M | −2.1% |
| Oct 29, 2024 | $0.79 est $0.67 | $186.0M est $198.6M | −5.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Harmony Biosciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Harmony Biosciences is $47.64, +24.6% from the last close, from 9 firms rating the stock in the last 90 days.
$47.64consensus 12-month target, +24.6% from the last close
Now $38.23Avg $47.64
Low $30High $60
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Mizuho Securities | $51 | +33.4% |
| Oct 12 | Bank of America Securities | $30 | −21.5% |
| Oct 1 | Deutsche Bank | $42 | +9.9% |
| Sep 25 | Mizuho Securities | $51 | +33.4% |
| Sep 24 | Needham | $50 | +30.8% |
+3.4%average 20-day move after past Accumulation readings
+7.3%average move over the next 20 trading days in the last 5 years
±3.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Harmony Biosciences seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Harmony Biosciences averaged +7.3% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.1% | 3 of 5 |
| Next 10 trading days | +0.4% | 4 of 5 |
| Next 15 trading days | +2.5% | 4 of 5 |
| Next 20 trading days | +7.3% | 4 of 5 |
| Next 30 trading days | +7.4% | 3 of 5 |
For scale, HRMY’s typical 20-trading-day move in either direction is about 8.6%.
Harmony Biosciences market cap and key statistics
Harmony Biosciences’s market cap is $2.21B, with a P/E ratio of 12.8 and revenue of $959.9M over the last twelve months.
Valuation
- Market cap
- $2.21B
- P/E ratio
- 12.8
- Forward P/E
- 10.1
- EPS, TTM
- $3.10
- Gekko Fair Value
- $63.51
Trading
- Volume
- 1.15M
- Avg volume, 20 days
- 976,186
- 52-week high
- $43.49
- 52-week low
- $25.52
- Shares outstanding
- 58.24M
Financials
- Revenue, TTM
- $959.9M
- Profit margin
- 18.9%
- Return on equity
- 20.5%
- Quarterly earnings growth, YoY
- +88.2%
Risk and income
- Beta
- 1.01
- Typical daily move
- ±3.9%
- Typical 20-day move
- ±8.6%
Harmony Biosciences stock news this week
6 headlines about Harmony Biosciences from the past week, newest first, each linking to the publisher.
- Why Harmony Biosciences Stock Got Mashed on MondayFool - Investing News, Oct 12
- Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down – What’s Next?Defense World, Oct 12
- Head to Head Review: Harmony Biosciences (NASDAQ:HRMY) versus PainReform (NASDAQ:PRFX)Defense World, Oct 12
- Harmony Biosciences names Peter Anastasiou as next CEO By Investing.comInvesting.com UK, Oct 12
- Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of GrowthYahoo Finance, Oct 12
- Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious HitInvestors Business Daily, Oct 12
Harmony Biosciences peers
Harmony Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Harmony Biosciences stock FAQ
What is Harmony Biosciences’s market cap?
Harmony Biosciences’s market cap is $2.21B at the Oct 12, 2026 close of $38.23, with 58.24M shares outstanding. The shares trade on a P/E ratio of 12.8.
What is the Harmony Biosciences stock forecast?
The consensus analyst 12-month price target for Harmony Biosciences is $47.64, +24.6% from the last close. Of the 9 firms that rated the stock in the last 90 days, 4 rate it a buy, 4 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Harmony Biosciences stock overvalued or undervalued?
On Gekko’s estimate Harmony Biosciences is undervalued: the Oct 12, 2026 close of $38.23 is 39.8% below Gekko Fair Value of $63.51. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Harmony Biosciences report earnings next?
Harmony Biosciences is expected to report on Nov 3, 2026, before the market opens (22 days away). Analysts expect earnings of $1.11 per share on revenue of $274.5M. Harmony Biosciences beat the earnings estimate in 4 of its last 8 reports, moving 5.8% on average across the report.
What is Harmony Biosciences’s 52-week high and low?
Harmony Biosciences’s 52-week high is $43.49 and its 52-week low is $25.52; it closed at $38.23 on Oct 12, 2026, +42.8% over the past year. Over the last five years the shares peaked at $62.09 on Dec 5, 2022.
Is Harmony Biosciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Harmony Biosciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.